Trouble Viewing This Email: Click Here

November 1, 2022


The Polaris Genomics Leadership Joins Rich Bendis on BioTalk

The Polaris Genomics Leadership team of CEO Charles Cathlin, MPH, CSO Tshaka Cunningham, PhD, and CMO Anne Naclerio, MD, MPH visit BioTalk to discuss competing in the 7th Annual Crab Trap Competition, being a Veteran-Owned Business and growing in BioHealth Capital Region.

Listen now via Apple, Google, or Spotify



Read More

Jennifer R. Butler Named 1st Executive in Residence by BHI and Montgomery County, MD

BioHealth Innovation, Inc. (BHI) and Montgomery County are pleased to announce Jennifer R. Butler as the first Montgomery County “Executive in Residence”—a pilot project dedicated to providing 1:1 technical assistance to Montgomery County-based biotech startups.  

This is a year-long collaboration between the county government, which is funding the work as part of its mission to grow the local life sciences cluster, and BHI, a regional innovation intermediary supporting technology commercialization throughout Maryland, D.C., and Virginia.


Read More

BioHealth Executive-In-Residence Montgomery County, MD

BioHealth Innovation, Inc. (BHI) has partnered with Montgomery County, Maryland to support entrepreneurs seeking to commercialize life sciences, digital health, and medical device technologies.  The new BHI-County agreement will fund one or more Executives in Residence, dedicated to cultivating the local life sciences ecosystem within Montgomery County.


Read More

2022 U.S. Market Entry Program for Korean Biohealth SMEs

20 weeks' journey of US Market Entry Program is finally completed. The program is to provide soft landing for medical start-ups from Korea. 5 start-up cohorts, after competitive selection, have been fostered by BioHealth Innovation (BHI) and KOSME (Korea SMEs and Startups Agency).

The synergy between strong Korean Government support and local expertise delivered significant impact to us. Congratulations to 5 cohort start-ups for successfully achieved the mission !


Read More

SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions

SIOUX FALLS, S.D. and GAITHERSBURG, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the company has entered into an exclusive manufacturing services agreement with Emergent BioSolutions Inc. (NYSE: EBS). Emergent will provide contract development and manufacturing (CDMO) services to produce SAB’s fully-human polyclonal antibody products. Currently, SAB has clinical-stage programs in pan-influenza treatment, treatment of acute and recurrent C. diff., prevention of Type 1 diabetes, and discovery assets in immunology and oncology.

Under the terms of the agreement, Emergent will provide end-to-end Good Manufacturing Practice (cGMP) manufacturing services to SAB, including process development and manufacturing clinical investigational drug product to support SAB’s clinical programs, and commercial manufacturing services upon regulatory approval of SAB’s therapeutics. The agreement also provides the opportunity for Emergent to utilize SAB’s novel DiversitAb™ platform, the only one in the world that produces fully-human polyclonal antibodies utilizing transchromosomic cows, for future development of undisclosed programs. Financial details of the agreement were not disclosed.

Read More

FUJIFILM Diosynth Biotechnologies and Maryland’s RoosterBio Announce Collaboration to Enable GMP Manufacturing of Cell and Exosome Therapies

Through this collaboration, FUJIFILM Diosynth Biotechnologies will incorporate RoosterBio's industry-leading process development technology for both MSC and extracellular vesicle (EV) / exosome programs into its manufacturing capabilities and offerings.


FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, announced today a strategic collaboration with RoosterBio, Inc., a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media, and bioprocess development services. Through this collaboration, FUJIFILM Diosynth Biotechnologies will incorporate RoosterBio's industry-leading process development technology for both MSC and extracellular vesicle (EV) / exosome programs into its manufacturing capabilities and offerings.

Read More

Adaptive Phage Therapeutics Appoints Edward Fang as Chief Medical Officer | Business Wire

GAITHERSBURG, Md.--(BUSINESS WIRE)--Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company advancing a phage bank, the world’s largest therapeutic phage initiative for treatment of bacterial infectious diseases, today announced the appointment of Edward Fang, M.D. as Chief Medical Officer. Dr. Fang’s responsibilities include overseeing clinical development for APT's phage bank treatment candidates through commercialization.

Tweet this “I am excited to welcome Dr. Fang, who brings broad expertise in therapeutic approaches to bacterial infectious disease and clinical trial execution to APT,” stated Greg Merril, CEO and Co-Founder of Adaptive Phage Therapeutics. “With Dr. Fang’s addition to APT’s leadership, I am confident that APT will achieve its short-term objective of rapidly progressing ongoing clinical trials, and longer-term objectives of leveraging expanding phage banks to deliver the first antimicrobials that adapt to the emergence of resistance. This approach does not decrease in coverage over time and will not require, or benefit from, market-suppressing stewardship.”


Read More

Maryland approved $8.2M to support STEM, innovation professorships at these 8 universities -

Thanks to the Maryland Department of Commerce, an octet of the state’s public and private universities can now commit a collective $16.4 million toward professorships in STEM, health and adjacent fields.

Half of that sum, or $8.2 million, comes from matching grants that the stage agency endowed via its Maryland E-Novation Initiative Fund (MEIF), which it administers to match private fundraising for endowed professorships and chair positions. The other half, per the MEIF’s mandate, came from private fundraising that the beneficiary universities and colleges raised.

Image: Holmes Hall, one of Morgan State University's main campus buildings. (Image via Facebook)


Read More


New Jeeva eClinical Research Technology Enables Global Diversity Inclusion and Multi-Center Collaboration


Diversity and inclusion in clinical trials are critical to achieving accurate and reliable results.(1) Participation in clinical trials is voluntary, and individuals of different ages, genders, races, ethnicities, genetic backgrounds, geographic locations, and environments will respond differently to the same treatments. An effective way to achieve diversity in clinical trials is through decentralization with standardized procedures across multiple sites.(2) To facilitate the efficient execution of multi-center clinical trials globally, Dr. Harsha Rajasimha, Founder and CEO of Jeeva Informatics, and his team have developed the modular Jeeva™ eClinical Cloud.


Read More

Tech Opportunity Webinar: "New Gene Therapy Method for Treating CRX-autosomal Dominant Leber Congenital Amaurosis (LCA)"

An NCI Technology Opportunity Webinar

We invite you to register and join us on November 15 from 11:00 am - 12:00 pm ET for a free NCI technology webinar.

Attendees will hear from Drs. Anand Swaroop, Ph.D. and Kamil Kruczek, Ph.D. of the National Eye Institute about a new gene therapy method for treating CRX-autosomal dominant Leber Congenital Amaurosis (LCA). LCA is a rare genetic disease that is responsible for about 20% of all childhood blindness. It’s caused by mutations in any of at least 25 genes that control photoreceptor development or function. LCA has both recessive and dominant forms. Currently, there is an FDA approved gene therapy for treating only one of the recessive forms of LCA caused by mutations in the RPE65 gene. In addition to most recessive forms, the dominant form of LCA with underlying mutations in CRX remains untreatable.


Read More

Venture capital will soon be brimming with ghosts | TechCrunch

“There’s more dry powder powder than ever before.”

“There’s never been a better time to start a startup.”

“Discipline is the new scale.” (OK, OK, I made that last one up, but didn’t you kind of believe it?).

The tech industry loves generalizations — and don’t worry, I enjoy my fair share too — but as the downturn continues to play out, it’s increasingly important to think about the structural changes that may be forming in the venture capital landscape. Venture firms, unlike unicorns, often don’t have hundreds of employees to cut. Instead, venture firms cut costs in quieter ways.


Read More


Home | About BHI | BHI News | Programs | Partners | Contact

Copyright AA(C) BioHealth Innovation 2022
All Rights Reserved.